CR20230323A - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents
Quinolinas y azaquinolinas como inhibidores de cd38Info
- Publication number
- CR20230323A CR20230323A CR20230323A CR20230323A CR20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- azaquinolines
- quinolines
- cancer
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que son inhibidores del CD38 y son útiles para el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163143245P | 2021-01-29 | 2021-01-29 | |
PCT/US2022/014221 WO2022165114A1 (en) | 2021-01-29 | 2022-01-28 | Quinolines and azaquinolines as inhibitors of cd38 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230323A true CR20230323A (es) | 2023-10-02 |
Family
ID=80446310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230323A CR20230323A (es) | 2021-01-29 | 2022-01-28 | Quinolinas y azaquinolinas como inhibidores de cd38 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11952377B2 (es) |
EP (1) | EP4284511A1 (es) |
JP (1) | JP2024506814A (es) |
KR (1) | KR20230141799A (es) |
CN (1) | CN117580829A (es) |
AR (1) | AR124718A1 (es) |
AU (1) | AU2022212035A1 (es) |
BR (1) | BR112023014898A2 (es) |
CA (1) | CA3208851A1 (es) |
CL (1) | CL2023002163A1 (es) |
CO (1) | CO2023009803A2 (es) |
CR (1) | CR20230323A (es) |
DO (1) | DOP2023000142A (es) |
EC (1) | ECSP23056223A (es) |
IL (1) | IL304466A (es) |
PE (1) | PE20232047A1 (es) |
TW (1) | TW202241418A (es) |
WO (1) | WO2022165114A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3147902A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
AU2012332297B2 (en) | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
BR112015022417A2 (pt) | 2013-03-14 | 2017-07-18 | Convergene Llc | métodos e composições para inibição de proteínas contendo bromodomínio |
CN107428733A (zh) | 2014-12-03 | 2017-12-01 | 葛兰素史克知识产权第二有限公司 | Cd38抑制剂和治疗方法 |
WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
CA3147902A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
TW202128677A (zh) | 2019-10-30 | 2021-08-01 | 美商米突倍基公司 | Cd38抑制劑 |
AR121759A1 (es) | 2020-04-07 | 2022-07-06 | Mitobridge Inc | Inhibidores de cd38 |
-
2022
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko unknown
- 2022-01-28 EP EP22704226.4A patent/EP4284511A1/en active Pending
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en active Application Filing
- 2022-01-28 JP JP2023544674A patent/JP2024506814A/ja active Pending
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2023000142A (es) | 2023-08-31 |
CN117580829A (zh) | 2024-02-20 |
IL304466A (en) | 2023-09-01 |
WO2022165114A1 (en) | 2022-08-04 |
CO2023009803A2 (es) | 2023-10-09 |
JP2024506814A (ja) | 2024-02-15 |
ECSP23056223A (es) | 2023-11-30 |
CA3208851A1 (en) | 2022-08-04 |
EP4284511A1 (en) | 2023-12-06 |
AU2022212035A1 (en) | 2023-08-03 |
CL2023002163A1 (es) | 2024-01-05 |
KR20230141799A (ko) | 2023-10-10 |
BR112023014898A2 (pt) | 2023-10-31 |
AR124718A1 (es) | 2023-04-26 |
US20220242862A1 (en) | 2022-08-04 |
PE20232047A1 (es) | 2023-12-27 |
TW202241418A (zh) | 2022-11-01 |
US11952377B2 (en) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
MX2022001019A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). | |
MX2022004513A (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MX2023010430A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). | |
MX2017012738A (es) | Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer. | |
MX2021006443A (es) | Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4). | |
PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
WO2019023315A3 (en) | RAC INHIBITORS | |
PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
CR20230323A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
MX2023005501A (es) | Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. |